Vyome Holdings, Inc. (NASDAQ:HIND) Short Interest Update
by Tristan Rich · The Markets DailyVyome Holdings, Inc. (NASDAQ:HIND – Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 76,872 shares, a growth of 272.0% from the November 30th total of 20,666 shares. Based on an average daily volume of 93,344 shares, the short-interest ratio is currently 0.8 days. Currently, 2.0% of the company’s shares are sold short. Currently, 2.0% of the company’s shares are sold short. Based on an average daily volume of 93,344 shares, the short-interest ratio is currently 0.8 days.
Vyome Stock Down 0.8%
Shares of HIND stock traded down $0.03 on Friday, reaching $3.73. The stock had a trading volume of 16,372 shares, compared to its average volume of 63,532. Vyome has a 12 month low of $3.57 and a 12 month high of $519.00. The stock has a market capitalization of $21.04 million, a price-to-earnings ratio of -0.03 and a beta of 1.21. The stock’s 50-day moving average price is $4.99.
Vyome (NASDAQ:HIND – Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($3.12) earnings per share (EPS) for the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 423.39%. The business had revenue of $0.04 million during the quarter.
Analyst Ratings Changes
Several equities analysts have recently issued reports on HIND shares. Citigroup raised shares of Vyome to a “buy” rating in a report on Thursday, October 2nd. Maxim Group reissued a “buy” rating and issued a $15.00 target price on shares of Vyome in a research note on Thursday, October 2nd. Wall Street Zen upgraded Vyome from a “sell” rating to a “hold” rating in a report on Thursday, October 9th. Finally, Weiss Ratings reissued a “sell (e-)” rating on shares of Vyome in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $15.00.
View Our Latest Report on HIND
Vyome Company Profile
ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.